Boston Scientific falls over 3% on weak guidance despite revenue beat
Boston Scientific (BSX) reported Q3 revenue of $5.14B, beating estimates, but EPS missed. Shares fell 3.48% pre-market due to weak Q4 and full-year guidance. The company cited a cybersecurity incident as a challenge. Cardiovascular and MedSurg segments showed modest growth, with mixed international results.
How this was made
The 30-second read
Why it matters
The guidance shortfall is likely to trigger sell‑offs in the stock and could influence sentiment toward the broader med‑device sector.
Market read
First report of weaker guidance for a large‑cap med‑device company; immediate price impact expected.
What to watch
International sales growth, especially in EMEA, may offset U.S. softness; the guidance includes a modest net‑sales decline that could be viewed as a strategic pause.
Background
Boston Scientific reported Q3 results that beat revenue estimates but missed EPS expectations, then provided weaker Q4 and full‑year guidance.
Ticker impact
Boston Scientific issued Q4 and full‑year guidance below analyst estimates, causing a 3.5% pre‑market drop.
downward pressure as investors price in lower earnings expectations
Guidance is materially below consensus and was released for the first time in this article.
Market effects
Medical‑device sector may face broader scrutiny as guidance shortfalls raise concerns about demand and cybersecurity risks.
U.S. healthcare stocks could see modest weakness in early trading.
Limited to investors with exposure to Boston Scientific and related med‑device peers.
Counterpoint
If the cybersecurity incident is resolved quickly, the guidance miss may be temporary and the stock could rebound.
Key entities
- CompanyBoston Scientific Corporation
Medical‑device maker that issued the guidance miss.
- ExecutiveMike Mahoney
CEO who commented on the cybersecurity incident.
